Clinical trial
A Phase 1 Study of PKI-179 Administered Orally to Subjects With Solid Tumors
NCT00997360 is registered in ClinicalTrials.gov with Wyeth is now a wholly owned subsidiary of Pfizer as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1 Study of PKI-179 Administered Orally to Subjects With Solid Tumors
- Lead sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Phase
- Phase 1
- Overall status
- Withdrawn
- Start date
- February 28, 2010
- Completion date
- February 29, 2012
- Enrollment
- 0 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
advanced malignant solid tumors